Mazdutide is an investigational dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist. It shows significant promise in clinical trials for treating...
Mazdutide is an investigational dual agonist that targets both GLP-1 and glucagon receptors, primarily being developed for the treatment of obesity and type 2 diabetes.
By activating both GLP-1 and glucagon receptors, Mazdutide helps reduce appetite, slow gastric emptying, and increase energy expenditure, leading to significant weight reduction and improved metabolic health.
Clinical trials have demonstrated that Mazdutide can achieve substantial weight loss and significant improvements in glycemic control, lipid profiles, and liver fat content in patients with obesity or type 2 diabetes.
No, Mazdutide is still an investigational drug and is not yet approved or available for prescription. It is currently undergoing various phases of clinical trials.